ReviewPLoS genetics2021
The Triangulation WIthin a STudy (TWIST) framework for causal inference within pharmacogenetic research.
Review in PLoS genetics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Appraising the Causal Role of Risk Factors in Coronary Artery Disease and Stroke: A Systematic Review of Mendelian Randomization Studies.Journal of the American Heart Association · 2023Pooled it
- Challenges and future directions for Mendelian randomization.Nature genetics · 2026Review
- Understanding the causes and consequences of low statin adherence: evidence from UK Biobank primary care data.BMC medicine · 2025Article
- Exploring and Accounting for Genetically Driven Effect Heterogeneity in Mendelian Randomization.Genetic epidemiology · 2025Article
- Triangulating Instrumental Variable, confounder adjustment and difference-in-difference methods for comparative effectiveness research in observational data.Wellcome open research · 2025Article
- Polygenic scores for cardiovascular risk factors improve estimation of clinical outcomes in CCB treatment compared to pharmacogenetic variants alone.The pharmacogenomics journal · 2024Article
- Article
- Calcium-channel blockers: Clinical outcome associations with reported pharmacogenetics variants in 32 000 patients.British journal of clinical pharmacology · 2023Article
- Genetically predicted on-statin LDL response is associated with higher intracerebral haemorrhage risk.Brain : a journal of neurology · 2022Article
- Statin treatment effectiveness and the SLCO1B1*5 reduced function genotype: Long-term outcomes in women and men.British journal of clinical pharmacology · 2022Article
- From pharmacogenetics to pharmaco-omics: Milestones and future directions.HGG advances · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
In this paper we review the methodological underpinnings of the general pharmacogenetic approach for uncovering genetically-driven treatment effect heterogeneity. This typically utilises only individuals who are treated and relies on fairly strong baseline assumptions to estimate what we term the 'genetically moderated treatment effect' (GMTE). When these assumptions are seriously violated, we show that a robust but less efficient estimate of the GMTE that incorporates information on the population of untreated individuals can instead be used. In cases of partial violation, we clarify when Mendelian randomization and a modified confounder adjustment method can also yield consistent estimates for the GMTE. A decision framework is then described to decide when a particular estimation strategy is most appropriate and how specific estimators can be combined to further improve efficiency. Triangulation of evidence from different data sources, each with their inherent biases and limitations, is becoming a well established principle for strengthening causal analysis. We call our framework 'Triangulation WIthin a STudy' (TWIST)' in order to emphasise that an analysis in this spirit is also possible within a single data set, using causal estimates that are approximately uncorrelated, but reliant on different sets of assumptions. We illustrate these approaches by re-analysing primary-care-linked UK Biobank data relating to CYP2C19 genetic variants, Clopidogrel use and stroke risk, and data relating to APOE genetic variants, statin use and Coronary Artery Disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.